Home » Driving CAR-T Drug Development with Flow Cytometry Insights

Driving CAR-T Drug Development with Flow Cytometry Insights

Created: January 15, 2025

In our CAR+T Drug Development Whitepaper, Ans De Beuckelaer, Regional Head Flow Cytometry EU, and Rowan Claeys, Clinical Biologist at Cerba Research, dive deeper into key elements of Flow Cytometry:
- The importance of Flow Cytometry in CAR+T clinical research and its uses
- Key aspects in developing a CAR+ T trial
- The added value of Flow Cytometry in multiple myeloma, Minimal Residual Disease (MRD) assessments, and multiple myeloma phenotype
- CAR+T-cell Therapy: patient treatment, targeted antigens and solutions for MRD assessments and multiple myeloma phenotype assessment.

Fill the form below to download the whitepaper.

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

First name*

Last name*

Email*

Company*

Job function*

Organization Level*

Region*

By submitting information on this form, you are agreeing to the terms of our Privacy Policy. You have the right to unsubscribe from email communication at any time.

Reach out to our experts and discover how we can help you transform your research in the field of flow cytometry or CAR T